If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Geographical indications protect the name of a product that has a specific geographical origin and owes its qualities, characteristics or reputation to its particular origin. Find out what they are, how the registration process works and what benefits they provide.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
278
results.
Updated on
31/08/2026 [07:07:00]
Results 225 to 250 of 278
Absstract of: WO2026174149A1
The present disclosure provides "stealth" LNP compositions (e.g., T cell-targeted LNPs (ctLNPs)) that surprisingly exhibit physiological characteristics of prolonged blood circulation time (e.g., increased blood t1/2) simultaneously with increased targeting capacity to T cells. The disclosed stealth LNP compositions are used for the treatment of autoimmune diseases and disorders.
Absstract of: WO2025078699A1
The current disclosure relates to targeted delivery of agents to T cells and/or NK cells. Highly suitable targeting domains were meticulously identified that allow for an agent, such as DNA and/or RNA, to be delivered to T cells and/or NK cells. As shown, when lipid nanoparticles were provided with such a targeting domain, nucleic acid comprised in said lipid nanoparticles was highly efficiently and specifically delivered. This allows for engineering of T cells and/or NK cells, highly useful in medical treatments for cancer.
Absstract of: WO2025080945A1
The present disclosure relates to lipid nanoparticles and methods of delivering active agents to target organs, tissues, or cells by utilizing the lipid nanoparticles.
Absstract of: WO2025080565A1
The present disclosure relates to a low glycosylated spike protein and a vaccine designed to express the spike protein in vivo. The present disclosure also teaches a method for generating an immune response by utilizing the low glycosylated spike protein, which provides a broader protection across different variants. A method for identifying a glycan-shielded conserved peptide of a glycoprotein is also disclosed.
Absstract of: WO2025080672A1
The present invention relates to methods and compositions comprising a delivery vehicle conjugated to a chemokine or cytokine ligand, wherein the delivery vehicle comprises at least one agent, and wherein the targeting domain specifically binds to the surface of a target immune cell. The invention also relates to methods for treating or preventing diseases and disorders, including cancers, infectious diseases, and immunological disorders, using the described delivery vehicle for delivery of a therapeutic agent.
Absstract of: WO2025080867A1
Provided herein are ionizable cationic lipids and lipid nanoparticle compositions comprising a lipid component comprising the same. Also, provided herein is a method of treating or preventing a disease or disorder in a subject in need thereof, the method comprising administering an effective amount of the lipid nanoparticle composition disclosed herein.
Absstract of: WO2025080572A1
A compound having the structure (I), (II), (III), or (IV) is provided: (I), (II), (III), (IV) ) where in these structures, (I), (II), (III), and (IV), each R1 is independently selected from aliphatic alkyl C4-C100 groups optionally substituted with one or more of alkenyl, alkynyl, hydroxyl, amide, ester, and/or ether groups; R2 is selected from -OCH2CH2-p or (A); R3 is selected from Formula (V) and Formula (VI): (V, (VI). M+ is selected from an alkali metal ion, an alkaline earth metal ion, or a primary, secondary or tertiary ammonium ion; and m, p, and s are independently selected from integers from 1 to 120. The compound is useful as a liver asialoglycoprotein receptor-targeted therapeutic agent in the form of a lipid nanoparticle, a liposome or a micelle including a drug or oligonucleotide.
Absstract of: EP4792824A1
0001 A peptide-based hydrogel for skeletal muscle regeneration, comprising: a) a self-assembling RADA16-I peptide forming a nanofibrous hydrogel matrix; and b) at least one bioactive peptide selected from: peptide fragment of stromal cell-derived factor 1 (SDF-1): SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 5, SEQ ID NO: 6, or peptide fragment of interleukin-4 (IL-4): SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 7, SEQ ID NO: 8, wherein the bioactive peptide is covalently linked to the RADA16-I sequence via a matrix metalloproteinase (MMPs) cleavable peptide linker and wherein cleavage of the linker by an MMPs results in controlled, localized release of the bioactive peptide in the microenvironment of regenerating muscle tissue.
Absstract of: EP4792807A1
0001 A problem to be solved by the present invention is to provide a carrier capable of being selectively delivered to cells at a subset level, which has not yet been realized by conventional art, and to provide a method for producing the carrier. The present invention relates to a carrier for selective delivery to a target cell having multiple types of target receptors on its surface, the carrier having multiple types of ligands, wherein each type of ligand binds to one of the multiple types of target receptors, wherein the carrier is taken up by the target cell that has all the multiple types of target receptors, but is not taken up by a cell that lacks at least one of the multiple types of target receptors; a method for producing the carrier; and the like.
Absstract of: WO2025080717A1
Methods for intranasal delivery of a GLP-1 (glucagon-like peptide-1) drug, such as tirzepatide (TZP), using a formulation of the drug encapsulated in poly(lactic-co-glycolic acid) (PLGA) nanoparticles coated with chitosan (CS) and/or polyethylenimine-grafted chitosan (CSPEI) at an optimized condition for surface charge change and particle size control. The resulting formulation successfully provides dosing-dependent body fat loss in mice, showing a significant therapeutic effect.
Absstract of: WO2025081194A2
Antigen-presenting nanoparticles and methods of engineering CAR T cells and treating and/or preventing cancer using the same.
Absstract of: WO2025077836A1
Provided herein is novel ionizable cationic lipid compound that can be assembled with other helper lipids, such as phospholipids, structural lipids, and polymer conjugated lipids capable of reducing aggregation, to form lipid nanoparticles for delivery of therapeutic RNA both in vitro and in vivo. These compounds contain a thiourea group in the linker between the lipid group and the head group (-NRc-C(S)-NRd-).
Absstract of: WO2025076625A1
Provided is a glutamic or glutaric acid-based ionizable lipid compound of Formula (I) or a pharmaceutically acceptable salt thereof. The compound can be used to obtain lipid nanoparticles. In some embodiments, the lipid nanoparticle can comprise (a) from about 40 to about 100 mol % of the compound of Formula (I); (b) from 0 to about 20 mol % of a neutral lipid; (c) from 0 to about 50 mol % of a helper lipid; (d) from 0 to about 5 mol % of a polymer-conjugated lipid; and (e) from 0 to about 10 mol % of a hydrophobic component; wherein the mol % are based on the total lipids present in the nanoparticle. In some embodiments, the ionizable lipid compound is a glutamic acid-based ionizable lipid compound.
Absstract of: WO2025080209A1
There is provided a compound represented by general formula (1) for preparing lipid nanoparticles encapsulating a therapeutic, prophylactic and/or biological agent: wherein AR comprises a unit from a poly(amino acid); R1 and R2 are each independently a hydrophobic group; R3, R4, and R5 are each independently H, optionally substituted alkyl, optionally substituted alkenyl or optionally substituted alkynyl; R7 is –H or –C(=O)R8, wherein R8 is optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl or optionally substituted alkoxy; m ≥ 1; and n ≥ 1.
Absstract of: WO2025081185A1
Disclosed herein are methods for delaying the onset of type I diabetes and preventing nosocomial infections by administering PEG-b-PPS nanocarriers loaded with rapamycin. This invention aims to reduce the frequency of visits to a transfusion clinic, reduce the costs of treatments, and reduce adverse side effects, without reducing the effects of the islet transplant. This is accomplished by the use of a nanocarrier which targets treatment to the desired location.
Absstract of: WO2025081013A1
The disclosures provides compositions comprising nanoparticles and a junction opener protein; and nanoparticles comprising one or more bioactive agents and a junction opener protein that is conjugated to the surface of the nanoparticles. Various bioactive agents are described, such as squalene, squalane, and dehydroisosqualene, among others. Various nanoparticle compositions are provided, including lipid carriers comprising a hydrophobic core. Methods for treating a subject with cancer by administering the compositions provided herein are also described.
Absstract of: EP3633042A1
A method for removing at least one impurity from metal-based nanoparticles, including at least two heating steps. During step 1, the temperature of the nanoparticles is increased to a temperature T1, and is then maintained at T1during a heating time that is included between 1 second and 20 years, where T1is included between 50 °C and 300 °C.During step 2, the temperature of the nanoparticles is increased to a temperature T2, and is then maintained at T2during a heating time that is included between 1 second and 20 years, where T2is included between 300 °C and 600 °C.
Absstract of: EP4793267A1
The disclosure features novel lipids and compositions involving the same. Lipid nanoparticles (e.g., empty LNPs or loaded LNPs) include a novel lipid as well as additional lipids such as phospholipids, structural lipids, and PEG lipids. Lipid nanoparticles (e.g., empty LNPs or loaded LNPs) further including therapeutic and/or prophylactics such as RNA are useful in the delivery of therapeutic and/or prophylactics to mammalian cells or organs to, for example, regulate polypeptide, protein, or gene expression.
Absstract of: US2023159926A1
Provided herein are compositions for gene modification or editing and methods of using same to treat or prevent certain conditions. Specific compositions and methods capable of safely and effectively editing gene targets expressed in the liver to durably lower LDL-C thereby treating a leading cause of cardiovascular disease are disclosed.
Absstract of: GB2605996A
A microbubble/microdroplet cluster composition for use in a method of treatment of a pathological condition of a mammalian subject is provided. The cluster composition is pre- and/or co- and/or post-administered separate to at least one immunotherapeutic agent (ITA). Ultrasound insonation at a first frequency and first mechanical index activates a phase shift of a diffusible component of the microdroplet into the microbubble to a form a larger bubble. A second insonation at a second frequency and second mechanical index is performed to enhance extravasation and uptake of the ITA. The ITA may be selected from the group of immune-oncology agents, monoclonal antibodies (mAbs), fusion proteins, soluble cytokine receptors, recombinant cytokines, small-molecule mimetics, cell therapies, cancer vaccines and oncolytic viruses. The ITA may be selected from the group of monoclonal antibodies anti-PD1, anti-PDL1 and CTLA4 and used in combination with a chemotherapeutic agent. The ITA may be selected from the group of immune checkpoint inhibitors. The cluster composition may be for use in treating localised pathological lesions, solid cancers, autoimmune diseases or for avoid rejection after organ transplant.
Absstract of: WO2025007059A1
Compositions and methods for making and using engineered cells, such as, engineered myeloid cells that express a chimeric fusion protein that has a binding domain capable to binding surface molecules on target cells such as diseased cells.
Absstract of: WO2025030134A1
Disclosed herein are compositions comprising (a) a nucleoside-modified polyribonucleotide encoding a Herpes Simplex Virus-2 (HSV-2) glycoprotein E (gE) antigen or immunogenic fragment thereof, (b) a nucleoside-modified polyribonucleotide encoding an HSV-2 glycoprotein I (gI) antigen or immunogenic fragment thereof, or (c) a combination thereof. Further disclosed are methods for using said compositions for treating an HSV infection.
Absstract of: WO2025026304A1
Provided are lyophilized formulations of lipid nanoparticles comprising a cationic lipid and a cryoprotectant combination, which contains sucrose and a non-polar amino acid.
Absstract of: TW202502729A
The disclosure provides ionizable lipids and lipid nanoparticle (LNP) compositions comprising ionizable lipids, helper lipids, neutral lipids, and PEG lipids useful for the delivery of biologically active agents, for example delivering biologically active agents to cells to prepare engineered cells. The LNP compositions disclosed herein are useful in methods of gene editing and methods of delivering a biologically active agent and methods of modifying or cleaving DNA.
Nº publicación: CN122582125A 18/08/2026
Applicant:
中国中医科学院中医基础理论研究所
Absstract of: CN122582125A
本发明提供了一种纳米姜黄素复合物及其制备方法和应用，属于生物医药技术领域。本发明提供的纳米姜黄素复合物中，插入功能性小分子肽段的神经元细胞膜作为外壳，内部包裹负载姜黄素的纳米粒子，能够显著提高姜黄素的溶解度和稳定性，促进其穿过血脑屏障并在脑组织中富集，同时有效抑制α‑突触核蛋白的磷酸化和异常聚集，从而在体内外模型中均表现出对长期低氧诱导的慢性神经损伤的显著保护作用。本发明为低氧相关神经系统疾病的预防和治疗提供了新的药物策略和理论依据。
BOPI
Electronic site
